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Introduction
The remarkable rate of development of medical knowledge
and pharmacology affects all medical specialties and in
particular general practice, since the latter embraces various
aspects of different medical fields.
Certain areas of medical practice, such as Hormone
Replacement Therapy (HRT), hypercholesterolaemia and drugs
affecting the Renin Angiotensin System (RAS) feature in a vast
amount of literature which is constantly being updated.  The
increasing awareness of the previously unknown effects of HRT
on one side, and the widespread prevalence of cardiovascular
disease in the case of hypercholesterolaemia and drugs affecting
the RAS have contributed to this large amount of studies.
On the other hand, certain areas of practice such as atopic
eczema and anti-thrombotic therapy have been rather quiescent
as far as developments are concerned, but revolutionary
treatments have recently been introduced in both areas, namely
the calcineurin antagonists and ximelagratan.  The latter is a
very promising drug which can replace warfarin, while the
former are the first steroid-sparing medications which
effectively control atopic eczema.
Keeping abreast with recent developments is a further
hurdle which the modern general practioner has to contend with
in order to offer valid treatment options, and to be able to answer
questions by increasingly well-informed patients.
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Hormone Replacement Therapy (HRT)
The issues surrounding HRT are controversial. Some of the
benefits ascribed to it include the relief of troublesome
menopausal symptoms, a decrease in the incidence of
cardiovascular disease and the prevention or treatment of
osteoporosis.  However, the Women’s Health Initiative Trial
(WHI)1 and the Million Women Study (MWS)2 cast doubt on
the validity of these claims.
The WHI was aimed to identify strategies that could
potentially lower the incidence of heart disease, breast and
colonic cancer, and fractures in healthy women.  The study
consisted of two arms, namely the oestrogen/progesterone
component, and the oestrogen alone component.  The latter
component is due to report in March 2005, but the former
component had to be stopped prematurely after there was an
excess of breast cancer disease and cardiovascular events in the
treatment group.  The combined hormone therapy resulted in
absolute excess risks of 7 more coronary events, 8 more strokes,
8 more episodes of pulmonary embolism, and 8 more invasive
breast cancers per 10,000 person years.
The findings of the WHI with respect to the effect of HRT
on the cardiovascular system have been supported by other
recent trials which have been carried out across different
categories of women.3,4,5
The Million Women Study was aimed at describing the
effects that different types of HRT had on the increase in
incidence of breast cancer.
Over one million females were recruited between 1996 and
2001. The study concluded that current users of HRT have a
relative risk of 1.66 of developing breast cancer and of 1.22 of
dying from it.  This relation was particularly evident in the
combined oestrogen-progestagen combination.
The above two studies have re-dimensioned the role of HRT
and the claims on its cardiovascular benefits are being
questioned, despite the observed beneficial effect HRT has on
the lipid profile.
HRT is effective in increasing bone mineral density and
reducing fractures in osteoporosis. But given the associated
increase in incidence of breast cancer, and above all the
availability of better alternatives such as bisphosphanates6, the
use of HRT for the treatment of osteoporosis is being re-defined.
Further more, after stopping HRT, there is a rapid decline in
bone mineral density which is not observed when
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bisphosphonates are stopped. In addition the results of studies
on new treatment options such as strontium ranelate are
promising7.
Hypercholesterolaemia
Since the publication of the Scandinavian Simvastatin
Survival Study (4S) in 1994, there has been an extraordinary
increase in interest concerning hypercholesterolaemia. The
Heart Protection Study8 (HPS) is only one of many important
studies published recently.
The aim of the HPS was to study the effects of using
simvastatin in high-risk individuals, irrespective of whether they
suffered from dyslipidaemia or not.  Over twenty thousand
adults suffering from some form of vascular occlusive disease
or diabetes were randomly assigned to receive simvastatin 40
mg daily or placebo.  A summary of the more important results
is provided in Table 1.
This was the first time that statins were used on people
without overt dyslipidaemia.  In addition, the study population
included adults up to the age of 80 years as well as a substantial
number of women. Both of these population sub-types have been
understudied or excluded in previous trials on statins.
The compliance rate for treatment in the HPS is claimed to
be 82%, with a special emphasis being made by the authors that
this is primarily attributable to the low incidence of side effects.
Although this high adherence rate may be true in the controlled
setting of a trial, it cannot be transferred to the community
setting, where adherence rates may fall down to about 25-40%.9
This study does not consider the fact that there are other issues
involved in compliance other than the side effect profile.
The HPS concludes that simvastatin is beneficial for people
at high risk of cardiovascular disease, even without
dyslipidaemia or actual evidence of vascular disease, by reducing
the incidence of new vascular events by nearly 25%.  These
findings have been further supported by the ASCOT (Anglo-
Scandinavian Cardiac Outcomes Trial)10 and PROSPER
(PROspective Study of Pravastatin in the Elderly at Risk)11
studies, where the same risk reductions were observed.
A meta-analysis12 published this year reviewed the benefit
of using statins in diabetic patients, and the Numbers Needed
to Treat (NNT) quoted are impressive:
• In Primary Prevention the NNT’s is 34, while
• In Secondary Prevention the NNT’s drops to just 13.
The publication of the HPS created some controversy and
offered issues for discussion.  It was the first time that people
without dyslipidaemia derived benefit from an anti-lipid agent,
and further confirmed the current trend of delivering treatment
to reduce overall cardiovascular risk and not merely treating
abnormal blood tests.  In addition, it has raised an issue about
the financial implications of giving statins to all people at high
risk of cardiovascular disease.
Finally there is always the dilemma over the desirable
cholesterol profile that clinicians should aim for.  Specific
guidelines have been provided by official bodies (Table 2),
however apart from a 35% reduction from the starting low
density lipoprotein (LDL) level, there is no universally accepted
threshold.
Headache
Headache is a common complaint especially Tension Type
Headache (TTH) and migraine.  The major underlying reasons
for consultation are reassurance about possible underlying
serious disease and relief of pain.
The diagnosis of headaches is mostly based on history taking
(Table 3).  The British Association for the Study of Headache
(BASH) guidelines for Tension-Type Headaches (TTH) and
Migraine13, released in 2003, are laid down in a clear manner
and are very helpful when dealing with this type of complaint.
In the case of migraine, when symptoms become
troublesome and frequent, the issue of prophylaxis arises. There
are numerous drugs which are used as prophylactic agents, but
none of them is 100% effective.
A recent study suggests that Angiotensin Receptor Blockers
(ARBs) may be an effective prophylactic agent 14.  This
Table 2: Guidelines of the European Society of Cardiology
1. For asymptomatic patients, aim for TC = 5mmol/L or
LDL = 3mmol/L, with the intent of lowering the CVS
risk to <5%.
2. For patients with clinically established CVD and
patients with diabetes treatment goals should be
lowered to TC = 4.5mmol/L or LDL = 2.5mmol/L.
{TC = Total Cholesterol; LDL = Low-density
Lipoproteins}
Adapted from European guidelines on cardiovascular disease
prevention in clinical practice Eur J Cardiovasc Prev Rehabil 2003;
10(Suppl 1): S1-S78
Table 1: Major Results of the Heart Protection Study8
Placebo Simvastatin Relative
Risk Reduction
First event rate of non-fatal MI or coronary death 1212 (11.8%) 898 (8.7%) 26.3%
Non-fatal or fatal Stroke 585 (5.7%) 444 (4.3%) 24.6%
Need of Coronary Revascularization 1205 (11.7%) 939 (9.1%) 22.2%
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randomized double blind, placebo controlled cross-over trial
was carried out in a neurology outpatient clinic, and recruited
60 adults known to suffer from migraine.  The 12 week treatment
period was divided into two phases. 30 patients received placebo
in the first phase and 16 mg candersartan cilexitil in the second
phase.  The other thirty received the candersartan followed by
placebo.
The number of days with headache was 18.5 in the placebo
group as opposed to 13.6 in the candersartan group. Also, there
was considerable amelioration of secondary endpoints in the
candersartan group.
Although carried out on a small scale, the conclusions of
this study follow on a previous one using lisinopril. Despite the
need to carry out further larger studies, these findings open new
horizons on the prophylactic treatment of migraine.
Alternative medicine in the form of acupuncture is also being
explored as a relief to chronic headache.  A recent study15 carried
out in a number of general practices in UK randomized 400
patients suffering from migraine or TTH to receive either
acupuncture or routine care from their GP.  The latter obviously
excluded referral for acupuncture.  Follow-up was for one year.
There was a 36% reduction in headache scores in the
acupuncture groups, and 22 % reported a reduction of more
than 35% of the original score.
Atopic Eczema
Atopic eczema is very common, and results in frequent
consultations at primary care level, in adults and children alike.
The mainstay of treatment includes a combination of steroid
creams/ointments, emollients and patient education in the
avoidance of allergens.
Although steroids are the treatment of choice when dealing
with “flare-ups” of eczema, they can have adverse side-effects if
used over a prolonged period of time.  Recently two potentially
revolutionary drugs, tacrolimus and pimecrolimus, have come
on the market.
These drugs are topical immuno-suppressants and function
by inhibiting inflammatory cytokine transcription in activated
T cells through inhibition of calcineurin.  Unlike steroids, they
do not affect other cells such as fibroblasts so they can be used
indiscriminately on any body area. However, they may cause a
slight burning sensation. Both of these agents are also licensed
for use in children above the age of  two.  There is currently an
application with the Food and Drug Administration (FDA) for
pimecrolimus to be licensed for children above 3 months of age.
A double blind study was also carried out to assess whether
early treatment with pimecrolimus could influence long term
outcome by preventing flare-ups.16  A random sample made up
of 713 patients between 2 and 17 years of age were prescribed
either pimecrolimus based treatment or conventional treatment.
After one year, the proportion of children in the control group
experiencing “flare-ups” was nearly twice as high as in the
pimecrolimus group (61% vs. 34.2%). Fewer “flare-ups” implies
that the need to use steroids as rescue medication decreases.
Being new, there is still some debate as to the exact place of
these drugs in the management of atopic eczema.  The British
Association of Dermatology Guidelines17 (2003) suggest that
they be used as second line treatment when conventional
therapy has failed or is not tolerated by the patient.  In addition,
it is recommended that tacrolimus be reserved for specialist use.
However, in certain particular situations, notably facial
eczema and diffuse eczema in children, it may be wiser to initiate
first-line treatment with these drugs.
Dyspepsia
Patients consulting family doctors because of dyspepsia
usually seek alleviation of symptoms and reassurance about the
possibility that their symptoms might be due to benign disease.
This consideration usually results in GPs referring patients for
endoscopy.  In fact, it is estimated that 1% of the UK population
undergoes gastroscopy each year.  Gastroscopy is an expensive
tool, and not devoid of side effects.
The role of the GP is to “triage” patients (Table 4) referring
only those suspected of having serious disease on triage or who
Table 3: British Association for the Study of Headache
recommendations for history taking and examination in
TTH and Migraine (2003)13
History
1. How many different types of Headaches are
experienced
2. Time Questions (onset, frequency)
3. Character Questions (intensity, quality, associated
symptoms)
4. Cause questions (predisposing, aggravating and
alleviating factors)
5. Response questions (activity limitation and
medications used)
6. State of health in between attacks
Examination
1. Check Optic fundi and blood pressure
2. In children check Head circumference and plot it
3. A thorough examination already reassures patient and
this is of benefit
Table 4: “ALARM” symptoms in dyspepsia
1. Anaemia
2. Loss of weight
3. Age (>55 years)
4. Recent onset of progressive symptoms  (<3 months)
5. Melaena
6. dysphagia
Adapted from ABC of the upper gastrointestinal tract
BMJ 2001; 323: 675
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fail to respond to treatment. A policy of Testing and Treating
(without using endoscopy) after triage is safe and effective, as a
recent study has shown.18
The trial was carried out in a hospital gastroenterology unit
and included a random sample of 586 patients. Patients
suspected of serious disease were immediately excluded. The
rest were referred to either endoscopy or breath testing. After
one year, the reduction in dyspepsia score was equal in both
groups. In addition, patient satisfaction was equal in both
groups. No potentially serious pathology was missed and only
8.2% of patients who underwent Testing and Treating
eventually required or asked for a gastroscopy.
The findings of this study have been confirmed in the
Scottish Intercollegiate Guideline Network (SIGN) Guidelines
for the Management of Dyspepsia issued in 2003.19
Angiotensin Converting Enzyme Inhibitors
(ACEI) and Angiotensin Receptor Blockers
(ARBs)
Since the landmark study SOLVD (Study Of Left Ventricular
Dysfunction) was published, the role and importance of ACEI
has changed.  Initially they were regarded as merely anti-
hypertensive medications, but recent studies have unraveled an
array of added beneficial effects, ranging from reduction in
cerebro-vascular accidents and progression of diabetic
nephropathy, to increase in survival in patients with left
ventricular systolic dysfunction after myocardial infarction20
Recently the EUROPA21 (EURopean trial On reduction of
cardiac events with Perindopril in stable coronary Artery
disease) assessed whether the use of ACEI (perindopril) reduced
the cardiovascular risk in a low-risk population with stable
coronary heart disease and no apparent heart failure.
This randomized controlled double blind study divided
12218 patients to  receive either perindopril or placebo.  The
mean follow-up was 4.2 years.  No details are given of the left
ventricular function of the patients, but it seems likely that most
had a normal ventricular function. There was a 20% relative
reduction in attainment of the primary end point in the
perindopril group (603 vs. 488).  The benefit shown by ACEI
on the CVS system may be beyond simple blood pressure
reduction, and possibly also dependent on dosage.22
ARB’s have seen a dramatic surge in popularity and two
trials highlighting the significant role of ARBs have recently been
published.
The CHARM23 (Candersartan in Heart failure Assessment
of Reduction in Mortality and Morbidity) was specifically
designed as three independent randomized controlled trials,
comparing the effects of candersartan in three different but
complementary populations of patients with symptomatic heart
failure.
• CHARM Alternative (n=2028) enrolled patients intolerant
of ACEI.  Candersartan significantly reduced both the risk
of hospitalization or death, with an overall risk reduction of
23%.
• In CHARM Added (n=2548) patients already stabilized on
ACEI had Candersartan added to their treatment. In
contrast with previous studies, there was a reduction in
death or hospitalization of 15%
• In CHARM Preserved (n=3025) patients with heart failure
and preserved left ventricular systolic function, candersartan
did not demonstrate a significant reduction in death.
The results of the individual trials have been grouped
together in the CHARM-Overall programme.
The VALIANT24 (Valsartan in Acute Myocardial Infarction)
trial assessed the effect of valsartan, captopril or a combination
of both over mortality in 14,703 patients with a myocardial
infarct complicated by heart failure or left ventricular systolic
dysfunction.  The primary endpoint was death.  In the valsartan
group the reduction in the risk of death was 25%, equivalent to
the captopril group.  No benefit was seen in using a combination
of ACEI and ARB; in fact this group reported most drug-related
side-effects.
Anti-thrombotic treatment
The role of anti-thrombotic therapy in the prevention and
treatment of cardiovascular disease has long been established
and the more frequently used drugs are aspirin and warfarin.
The Anti-Platelets Collaboration of 1994 reviewed 145
studies, and unequivocally showed the benefit of using aspirin
to prevent serious vascular events in a range of high risk patients
(unstable angina, myocardial infarction, transient ischaemic
attacks, peripheral vascular disease, and after vascular
procedures). In fact the reduction in adverse vascular events
was around 25%.
A new review of 287 trials was published in 200225, with the
aim of addressing certain areas which were left unanswered by
the previous meta-analysis.  The findings of the first meta-
analysis have been confirmed.  New information added includes:
• The recommended dose of aspirin is 75-150 mg daily. The
first meta-analysis had failed to identify an adequate dosage
and suggested a range from 75-325 mg daily.
• Clopidrogel is an effective alternative to aspirin in people
intolerant of aspirin.
Warfarin has long been used as the only oral anti-coagulant
in a variety of clinical scenarios to reduce systemic embolic
events and stroke.  Unfortunately, its efficacy is shadowed by
the numerous drug interactions and the need of regular INR
monitoring.  People who are at low risk and could be managed
in a community setting are still being followed up in secondary
care due to these undesirable effects. However things may
change with the advent of ximelagratan.
Ximelagratan is an oral direct thrombin inhibitor.  After oral
administration it is rapidly metabolized to its active form
melagratan.  Potential benefits of ximelagratan are
adminstration on a fixed twice daily schedule without the need
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of altering the dosage and it does not need any type of blood
monitoring.   It is practically devoid of any relevant interactions
and the main mode of excretion is via the kidneys.
Two phase III trials26 compared the effect of ximelagratan
to warfarin in preventing stroke in patients with atrial fibrillation
deemed to be at high-risk. The pooled results showed that
ximelagratan is as effective as warfarin while there was a lower
incidence of major and minor bleeds with ximelagaratan.  The
only problem with this new drug is that elevation of liver
enzymes was noted in 6% of the study population.
Ximelagratan was also studied in the secondary prophylaxis
of myocardial infarction27 and patients who suffered a
myocardial infarction were given aspirin and randomized to
different dosages of ximelagratan. The combined therapy,
irrespective of which dose of ximelagratan was used reduced
the primary end point of all cause mortality, non fatal MI or
recurrent ischaemia from 16.3% to 12.7%.
The role of ximelagratan has still to be defined, and may be
more appropriate in low risk scenarios.  Certainly more studies
need to be carried out to confirm its efficacy and review the
potential side effects.  However, it provides a new exciting tool
for the general practitioner and also a less cumbersome
treatment for the patient.
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